TY - JOUR
T1 - Fluoxetine treatment for weight reduction in steroid-induced obesity
T2 - A pilot study in myasthenia gravis patients
AU - Achiron, Anat
AU - Barak, Yoram
AU - Noy, Shlomo
AU - Pinhas-Hamiel, Orit
PY - 1999/1/1
Y1 - 1999/1/1
N2 - To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration. Thirteen myasthenia gravis, overweight, long-term steroid-treated patients [age: 31-59, body mass index (BMI): 29-54 kg/m2] were included. Measurements of weight, BMI, and routine laboratory tests, were undertaken at baseline, 12 and 24 weeks. Muscle strength and fatigue parameters were assessed at 4 week intervals. Fluoxetine induced mean weight loss of 7.7 ± 2.6 kg and 10.3 ± 2.9 kg over a period of 12 and 24 weeks respectively, (P < 0.05). Mean BMI decreased from 35.8 to 32.2 kg/m2 over the study period. No significant side effects were noted. We conclude that patients suffering from steroid-induced obesity respond to fluoxetine treatment of overweight by significant weight loss.
AB - To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration. Thirteen myasthenia gravis, overweight, long-term steroid-treated patients [age: 31-59, body mass index (BMI): 29-54 kg/m2] were included. Measurements of weight, BMI, and routine laboratory tests, were undertaken at baseline, 12 and 24 weeks. Muscle strength and fatigue parameters were assessed at 4 week intervals. Fluoxetine induced mean weight loss of 7.7 ± 2.6 kg and 10.3 ± 2.9 kg over a period of 12 and 24 weeks respectively, (P < 0.05). Mean BMI decreased from 35.8 to 32.2 kg/m2 over the study period. No significant side effects were noted. We conclude that patients suffering from steroid-induced obesity respond to fluoxetine treatment of overweight by significant weight loss.
KW - Fluoxetine
KW - Myasthenia gravis
KW - Obesity
KW - Steroids
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=0032969733&partnerID=8YFLogxK
U2 - 10.1016/S0924-977X(98)00012-1
DO - 10.1016/S0924-977X(98)00012-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 10082236
AN - SCOPUS:0032969733
SN - 0924-977X
VL - 9
SP - 111
EP - 113
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 1-2
ER -
